Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug Rezetecan vs Standard of Care in Platinum-resistant Ovarian Cancer
NCT07286266Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Primary completion
- Jul 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of mocertatug rezetecan in ovarian cancer, sponsored by GSK. Started Jun 2026; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07286266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286266.